



# *The Edmond J. Safra Fellowship in Movement Disorders*




*Fall 2024*



EDMOND J. SAFRA  
PHILANTHROPIC FOUNDATION



THE MICHAEL J. FOX FOUNDATION  
FOR PARKINSON'S RESEARCH






*“I’m proud and humbled to see the seeds of our partnership with the Edmond J. Safra Foundation flourish in the most incredible way.”*

For people and families with Parkinson’s, seeing a movement disorder specialist is a game-changer. But the reality is that there are simply not enough of these specially trained neurologists, and that’s one of many reasons why not enough Parkinson’s patients get to the right doctor.

In 2014 The Michael J. Fox Foundation called on the vision of our longtime partner the Edmond J. Safra Foundation to support a durable strategy to train more movement disorder specialists. The Edmond J. Safra Fellowship in Movement Disorders was purpose-built to allow more people with Parkinson’s to experience what’s possible

with the right care — from a doctor who possesses specialized training and deep experience in this disease. Ten years later, my dear friend Lily Safra’s legacy of compassionate care continues with each new class of fellows.

I’m proud and humbled to see the seeds of our partnership with the Edmond J. Safra Foundation flourish in the most incredible way. And I’m tremendously grateful to our fellows and fellowship directors. Their commitment will bring us to our collective goal: A day when Parkinson’s is a curable, and even preventable, condition.



“The Edmond J. Safra Fellowship uniquely positions its graduates as emerging leaders, experts who care for people and families living with disease today while working toward a future in which Parkinson’s, as we know it, no longer exists.”

**R. Do** 

Rachel Dolhun, MD, DipABLM  
Principal Medical Advisor  
The Michael J. Fox Foundation for Parkinson’s Research

# Table of Contents

- 04 Making a Global Impact on  
Parkinson's Care and Research
- 06 Illustration  
*A Decade of Network Growth and Collaboration*
- 12 Recent Graduates  
*Class of 2024*
- 22 Fellowship Directors  
*Class of 2024*
- 26 Career Development Awards
- 28 Fellows  
*Classes of 2025 and 2026*
- 30 Fellowship Centers  
*Class of 2027*
- 32 A Decade of Training Leaders

# *Making a Global Impact on Parkinson's Care and Research*

---

Ten years ago, the Edmond J. Safra Foundation and The Michael J. Fox Foundation (MJFF) came together over a central challenge: how can we foster scientific advances in Parkinson's research while also meeting the growing need for trained specialists who can diagnose and care for the needs of people living with PD? The answer came in the launch of the Edmond J. Safra Fellowship in Movement Disorders, formed in partnership with MJFF.

This partnership created a new opportunity to shape Parkinson's care as a complement to research. The need for these resources is real. The number of people diagnosed with Parkinson's is expected to double by 2040, and with it the demand for movement disorder specialists will also increase. But advancing Parkinson's care goes beyond the bedside: it also means leading the research that can be transformative to patient care.

The Edmond J. Safra Foundation has been our dedicated partner in this endeavor, expanding the ripple effect of its long history as our partner in the work to develop better therapies and a cure for Parkinson's. Since our earliest

days, the Edmond J. Safra Foundation has provided sustained support for every one of our top scientific and care priorities. Its impact is felt and seen in the incredible accomplishments in the past 10 years since the Fellowship began, including the validation of the new biomarker in our Parkinson's Progression Markers Initiative and a new genetic link for PD found in underrepresented populations via our GP2 initiative, both supported by the Edmond J. Safra Foundation. The 19 new treatments for Parkinson's approved in the United States in the past decade attest to its deeply ingrained support and the importance of the Fellowship and its network now more than ever — furthering research advances and delivering them directly

to patients, while connecting them to the research that propels us forward.

A decade after its launch, the impact of the Edmond J. Safra Fellowship in Movement Disorders is indisputable. The Fellowship is a renowned and distinguished training program that has built a global network that extends care access, including in underserved areas; fuels research advances; and trains future generations beyond trainees. Centers and trainees seek out this opportunity, knowing it signals the highest quality education. People with Parkinson's and their families know that with the training, our graduates will deliver the most skilled and compassionate care.

Our influence has extended far beyond the U.S. A unique and highly valued feature of the program – extending education, mentorship and partnership opportunities beyond a trainee's individual center – has helped the network grow to 51 centers in four continents, 12 countries, and across 14 states in the United States. With 56 Fellowship directors, 40 graduates and 16 in training, there are 112 clinician-scientists driving research and patient care across the globe. For an estimated 31,200

people, that means they have care that, without this training program, would not be there.


The Edmond J. Safra Foundation's support has never been more critical than in the current moment, when the momentum is building around new drug development and research breakthroughs accelerated by the new biomarker validated last year. As we enter the new era of Parkinson's research, and with the growing need for trained specialists to address the unmet needs of patients, it will be the capable and dedicated leaders of the Fellowship who will sustain and grow the incredible momentum that has brought us to this point. This next generation of clinician-researchers are uniquely positioned to usher in the next chapter of research and care.

The vision, generosity and sustained partnership of the Edmond J. Safra Foundation has enabled the Fellowship to make a global impact on the Parkinson's community. We are deeply grateful for your generous and visionary support, which has altered Parkinson's care and research forever.

—The Michael J. Fox Foundation

# Expanding Parkinson's Care: A Decade of Innovation and Growth

In 2014, The Michael J. Fox Foundation, with the support of its longstanding partner the Edmond J. Safra Foundation, identified a critical need for more movement disorder specialists. Ten years later, a unique global network of specialists trained by the Edmond J. Safra Fellowship in Movement Disorders is expanding access to patient care and fueling research.



**2014**  
The Edmond J. Safra Fellowship in Movement Disorders launches.

**2015**  
First five centers and Fellows are selected for the inaugural class of 2018.


**2016**  
First Fellowship class begins two-year training.

**2017**

**2018**  
First class of five Fellows graduates.

**2019**





2024

40

Graduated  
Fellows

16

Fellows in  
Training

56

Fellowship  
Directors

34

Fellowship  
Centers

2020

2021

With generous support from the Edmond J. Safra Foundation, the number of centers funded annually increases to eight.

2022

2023

2024

First class of eight Fellows graduates.

2028


With pledged funding from the Edmond J. Safra Foundation, the program will graduate a total of 73 new movement disorder specialists around the world.

# Leaders in the Transformative New Era of Parkinson's Research

Over the last 10 years, Fellowship-trained movement disorder specialists have powered the bench-to-bedside pipeline. They have been leaders in research amid the growing momentum for new drug development and scientific breakthroughs accelerated by the new Parkinson's biomarker.



**The alpha-synuclein biomarker** was validated in 2023 through MJFF's Parkinson's Progression Markers Initiative (PPMI).



"The ability to see how new diagnostic tools are aiding our patient care has been invaluable in teaching me the importance of good research in clinical care."  
*Emily Tharp, MD; Class of 2025*



The Global Parkinson's Genetics Program (GP2) has advanced understanding of **novel genetic variants** that contribute to Parkinson's.



"My research team's discovery of a new gene implicated in early-onset Parkinson's would have not been possible without the support of the Edmond J. Safra Fellowship, the Career Development Award, my mentors and the Fellowship network."  
*Francesca Magrinelli, MD, PhD; Class of 2023*



**19 new Parkinson's treatments** have been approved since 2014 for use in the U.S.



"The Edmond J. Safra Fellowship has taught me how to design, initiate, execute and manage both prospective clinical trials and retrospective studies."  
*Jun Yu MD, MS; Class of 2024*

# An Expanding Network Improves Access to Parkinson's Care

Graduates of the Edmond J. Safra Fellowship in Movement Disorders bring care to underserved regions, serve a greater geographic area as they relocate and increase patient access to care.




12 Countries



34 Fellowship Centers



Network Expansion Through Graduate Relocation



“Being one of only four movement disorder neurologists in the state of Arkansas, an underserved area of the country, has been a profoundly gratifying experience.”

*Aditya Boddu, MD; Class of 2022*

A world map with a dark blue background and white landmasses. Orange location pins are placed across various continents, including North America, South America, Europe, Africa, and Australia. Some pins have a white and orange striped pattern.

Each of the 40 graduates to date  
care for an average of

**780\***  
patients a year



**31,200**  
**PATIENTS**


worldwide have access  
to specialized  
Parkinson's care

Inset: Australia

*\* Based on 2024 surveys of  
Fellowship graduates and trainees*

# Collaboration Creates a Ripple Effect

Fellows are partnering together to improve our understanding of Parkinson's, advance new treatments and create additional training opportunities.




# *Recent Graduates*

Class of 2024

# Class of 2024

## Laura Armengou-García, MD

Toronto Western Hospital  
Toronto, Canada



### Charting a Clear Path

Growing up in Seville, Spain, my parents were wonderfully supportive, spending quality time with me, while they also worked weekends and late nights. I learned from them that being disciplined and devoting time to my interests would help me reach my goals and dreams. My uncle and great-grandfather were pediatricians, so my taste for medicine runs in the family. What's more, my grandfather, who passed away six years ago, suffered from Parkinson's disease. I'd accompany him to his neurologist and admire how the doctor carried out the clinical examination. That same doctor happened to teach me neurology at the medical school in Seville, and I ultimately did my senior thesis with him. Then, I did my residency in neurology at the Clínica Universidad de Navarra in Pamplona, Spain.

### Connecting Research and Care

To treat patients and understand diseases, we need to know more about them. The only way to do this is through basic and clinical research, so we can develop new treatment targets. My greatest achievement during the Edmond J. Safra Fellowship has been participating in various research projects. In particular, I've enjoyed working on Parkinson's biomarker studies and clinical trials targeting Parkinson's genes. We're in the beginning of a new era in Parkinson's


research, which is stimulating, encouraging and exciting. The academic environment at Toronto Western Hospital has been exceptional. Under the supervision of Dr. Susan Fox and Dr. Anthony Lang, working in a highly qualified unit dedicated entirely to the care of neurodegenerative diseases helped me to understand the importance of having colleagues with different roles, collaborating to achieve the same goal.

### Beginning a New Career

Being an Edmond J. Safra Fellow has allowed me to deepen my clinical and research skills and create a new network of colleagues with whom I can share ideas and build new projects. There have been many valuable meetings and opportunities for collaboration. I'll enjoy special time with my family this summer after giving birth to my first child. Following maternity leave, we'll move to Quebec City, where I'll take up a new position as a neurologist specializing in movement disorders at the CHU de Québec-Université Laval, known for its basic science research program. I aim to help develop the movement disorders unit with more clinical research, while caring for patients. I'll also have an academic role at Laval. And in the fall, I'll defend my doctoral thesis on PD and subthalamotomy, a surgical treatment option to treat PD symptoms.

## Milan Beckers, MD, MSc

Radboud University Medical Center  
Nijmegen, Netherlands



### **Being There for Patients**

I'm from the province of Friesland, Netherlands. I always had an internal drive to gather knowledge and learn new things. My parents were very supportive of my goals. My love for science led me to the University of Groningen for medical school, but a personal experience further influenced me. My father received an incurable cancer diagnosis in the presence of people he didn't know, including nurses and other patients. Later, when the oncologist told him his cancer progressed, it was a shock. We had so many questions but we were simply seen out. Since then — including throughout my neurology residency at Zuyderland Medical Center — I always make sure that I set the stage right for my patients, and that I deliver difficult news in the presence of people whom the patient wishes to be there. In neurology, the history-taking and physical exam can give such important clues. This hands-on approach can also help patients cope. They understand that I have listened, done a thorough exam, felt the stiffness, seen the tremor. We take a lot of time with our patients, and I think all of this helps patients accept their diagnosis and the journey ahead.

### **Studying Levodopa Resistance**

The topic of my PhD research project is levodopa, the most commonly used medication for Parkinson's. Up to 20 percent of PD patients don't respond well or at all to it. One reason for levodopa resistance is that the gastrointestinal system may absorb it badly, especially where many PD patients have GI issues. So, levodopa won't reach the brain in sufficient quantities. We're setting up the first clinic in the Netherlands to care for and manage PD patients with levodopa resistance.


### **Advancing Equity in the Netherlands**

I'm excited to stay here at Radboud University Medical Center for two more years to finish my research. My supervisor, Dr. Bas Bloem, opened my eyes to how the knowledge gained through a PhD can advance clinical care. I'm also part of an effort to connect nursing homes and hospitals to address and improve Parkinson's disease care in the significantly growing elderly population. As a Fellow, I was also part of a working group to identify challenges related to diversity and access to care in the Netherlands, which we want to understand better and work on so that everyone with PD gets the care they need.



## Stephen Berger, MD, PhD

Johns Hopkins University  
Baltimore, Maryland



### **Catching the Research Bug**

My mom is a palliative care specialist and my dad is an engineer, so science and learning were encouraged from a young age. They'd take me to children's science museums. They gave me a little toy microscope where I'd take an eyedropper of water from the backyard and look at what was moving around in that drop. Those early experiences influenced my choice to pursue neurology. For four summers in high school and college, I volunteered in a National Institutes of Health Lab that studies the genetics of neurological diseases. That's where the research bug hit me. Around the same time, my grandfather's Parkinson's disease was progressing. Seeing his health decline had a major impact on me. He passed away as I was applying for MD-PhD programs. I knew I'd end up in movement disorders, in large part because of this personal experience. I was drawn to the combination of scientific curiosity about the brain's nuts and bolts, and the extent to which the brain is the origin of so much of what makes us human: our personalities, relationships, interests and ability to interact with the world.

### **Learning from Patients and in the Lab**


I attended Johns Hopkins University for college, then spent 13 years at New York University for my MD-PhD and my neurology residency. Now, back in Baltimore at Johns Hopkins, I've been able to see a lot of patients — many with rare diseases or uncommon presentations — and I've learned a tremendous amount from patients and families while working with a large, interdisciplinary group of physicians and scientists. I also joined the lab of Drs. Ted and Valina Dawson, who have done a lot of work on the cell biology of Parkinson's disease. My particular interest is in Parkinson's dementia and dementia with Lewy bodies — closely related cognition disorders that aren't as well understood as Parkinson's disease. Under the microscope, these two dementias seem to have a lot of features of both Parkinson's and Alzheimer's disease. I'm using stem cells that we can grow in a dish to model the overlapping pathology between Parkinson's and Alzheimer's, and to explore basic questions of why brain cells get sick and die in these two forms of dementia. Ultimately, we want to design better treatments based on understanding better this overlapping pathology and bolster the treatments coming into the pipeline for Parkinson's and Alzheimer's.

# Class of 2024

---

## José Ricardo López Castellanos, MD

Emory University  
Atlanta, Georgia



### **Connecting Early to Patients and Families**

I've been connected to Parkinson's and Alzheimer's disease populations since growing up in San Salvador, El Salvador. My father is a movement disorders specialist who founded a Parkinson's support group that met on Saturday mornings when I was a kid, and I'd go with him. I found a remarkable, resilient and united patient population, eager to help each other. That was one reason why I felt inspired to work with this group throughout high school, after graduating from the Dr. José Matías Delgado Medical School, and today. I completed my residency at the University of Arkansas for Medical Sciences and was at Emory University for the Fellowship. Here, the many subspecialists working together in movement have provided tremendous learning opportunities. Discussing and managing cases together and working in the dystonia, ataxia and Parkinson's disease comprehensive care clinics has been invaluable. I feel very passionate about movement disorders — and with the special bond that my father and I share in this field, it makes the work even more enjoyable.

### **Diving into DaTscans**

One project I've been working on during my Fellowship is the utilization of DaTscan. This imaging test helps differentiate neurodegenerative parkinsonism from other

conditions, including drug-induced parkinsonism and essential tremor, and since patients often come to us with very complicated cases that need a second or third opinion, DaTscan can help. I am researching how it is used overall at our center, what patients' diagnoses are before the scan is done and how much diagnoses change after using it. Under Dr. Stewart Factor's mentorship, I'm also looking at drug-induced movement disorders and their comprehensive management.


### **Educating and Empowering Patients**

Next year, I'll pursue an autonomic disorders specialty studying autonomic body processes like heart and blood pressure — a much needed specialty in Parkinson's care — at Beth Israel Deaconess Medical Center in Boston. I will also continue outreach, education and empowerment for patients and family members with Parkinson's and other movement disorders — both in the U.S. and in Latin-American countries. U.S. Spanish speakers who need a translator every time they come to the clinic can be afraid; they may not know what questions to ask if they have Parkinson's. If they're able to know what the disease means, how the symptoms can be controlled and what is within their reach to improve or maintain, we can empower them.

---

## Leila Saadatpour, MD

Cleveland Clinic Foundation  
Cleveland, Ohio



### **An Inspiring Family**

My dad is a radiologist in our hometown of Isfahan, the second largest city in Iran. I'd go to the hospital with him a lot and became very familiar with the environment. I enjoyed watching him and seeing how much he loved his job. His work ethic made a big impression on me.

### **Making My Own Mark**

By the time I got to high school, though, I thought I wanted to do something different from my dad and my older sister, who was already in medical school, and I wanted to become an architect. But by my final year of high school, I realized that I wouldn't be happy if I wasn't in medicine. That's what I decided to pursue. After finishing medical school in Isfahan, I came to the U.S. and did two years of research. Then, I completed my residency at the University of Texas at San Antonio, where an Edmond J. Safra Fellowship alumna, Dr. Sarah Horn, mentored me. I'll be returning to work with her in the movement disorders clinic there as an assistant professor, after I complete my Fellowship at Cleveland Clinic.

### **Combining Care with Research**


Going into neurology was an easy choice. I love both the clinical and research aspects. I love how much magic we can do to make someone feel better. There's a lot we can offer, and there's so much more coming in the future with new treatments. Combining clinical work with research keeps us on top of things. There are a lot of advancements today, and if you're not active in research you may not grow your mindset in how to treat patients. For example, I've been using publicly available data from the Parkinson's Progression Markers Initiative, plus artificial intelligence, to try to predict cognitive outcomes in Parkinson's patients. I've also been studying a common Parkinson's medication, amantadine, the commercially available treatment for dyskinesia. It's a mystery how amantadine works, because for some patients it's great, but not everyone responds well. We decided to do a study looking at whether genetic factors influence drug response. I'm excited to see what we find.

# Class of 2024

---

## Christina B. Swan, MD, PhD

Rush University Medical Center  
Chicago, Illinois



### **Hometown Affinity**

I'm proud to be a New Jersey girl, having been born and raised there with wonderful family and friends. My grandmother lived with us. She was my role model and gave me the mindset that I could figure anything out. My mom and dad, both engineers, helped me develop whatever I showed an interest in — which happened to be science and building things. In fourth grade, I did a report on sharks and we used my erector set to build a shark whose mouth moved. I was very proud of it.

### **A Passion for Patient Care**

To me, neuroscience is like working with a living computer, the brain, so first I focused on brain machine interfaces as an undergraduate student at Dartmouth College. Then I went to Duke University for my MD-PhD, a path I chose so I could work with patients and research. As soon as I started interacting with patients, everything reversed for me. I went from focusing primarily on deep brain stimulation (DBS) and biomedical engineering to loving the direct connection with patients. So, I changed my focus from mainly doing research to becoming a clinician carrying out clinically based research.

### **Refining Deep Brain Stimulation**

I've been training to assist surgeons in the operating room, implanting DBS electrodes. On the research side, I'm looking at patient outcomes from DBS surgeries to compare how they have done when they are awake versus asleep. Traditionally, DBS surgery happens with the patient partially awake, because you can do a recording and listen to the brain cells to help with implant precision. But today, thanks to very high-resolution imaging, you can also get excellent results by implanting those electrodes with the patient fully asleep. Because a patient's head must be secured to the operating table, the traditional awake procedure doesn't work for patients with severe post-traumatic stress disorder, claustrophobia or dystonia. If the asleep version is just as effective, then it opens the procedure to many more people who could benefit from it.

### **Fulfilling a Dream**

As I stay on at Rush as an assistant professor, I'll work in movement disorders, continue assisting with DBS procedures in the operating room and join a prospective study comparing awake versus asleep outcomes using new data that we'll collect from DBS surgery patients. The interactions with every one of my patients and trying to make things better fulfill me.

---

# Rebecca Williamson, MD, PhD

University of Pennsylvania  
Philadelphia, Pennsylvania



## **From Neurons to Neurology**

I remember learning about a neuron and an action potential while in high school, and how these action potential signals progress along a neuron to communicate with other neurons. I was amazed that this is how our bodies work and it's how we have thoughts and feelings, transfer those into movements and make decisions.

After high school, I left my hometown outside of Toronto, Canada to study neuroscience through a combined BA/MA program at Johns Hopkins University. Then, it was on to Columbia University for my MD-PhD, and I completed my residency at Massachusetts General Hospital and Brigham and Women's Hospital.

## **The Power of Teamwork**

I fell in love with rowing in high school. You work as part of a whole unit, especially on larger boats with eight rowers and a coxswain directing you. It's the ultimate team sport. It's very similar here at the University of Pennsylvania. A team of clinicians, social workers, advanced practice providers, therapists and clinical research coordinators works together. With their partnership, I've learned to care for the whole patient in both the general movement disorders clinic and cognitive clinics. A team here, led by my mentor, Dr. Dave Irwin, follows patients with

rare cognitive disorders and atypical parkinsonisms throughout their lives with imaging, biomarkers and neuropsychiatric testing. The patients then donate their brains at death. We use a very high-powered MRI to get high-resolution images of the brain — we can correlate molecular and structural analysis with all the data from a person's life.

## **Researching Biomarkers**


I'm looking at the basal ganglia within frontotemporal dementias and atypical parkinsonisms to see if a radiographic biomarker, like we have in Alzheimer's, can give us a better sense of underlying pathology in the brain. We've found some changes that might be able to predict the type of protein that accumulates in the brain of someone diagnosed with frontotemporal dementia. This is an essential step to ultimately target those proteins and treat the patient while they're living. I will stay at the University of Pennsylvania as an assistant professor and will work in the movement disorders and cognitive neurology clinics. It's amazing to be able to give patients a name and a diagnosis for what they are experiencing and offer hope that new medications are coming onto the market that could really help them.

# Class of 2024

---

## Jun Yu, MD, MS

Norman Fixel Institute for Neurological Diseases at University of Florida Health Gainesville, Florida



### Connections in the Brain

I developed a kinship with healthcare providers very early on. I grew up in an apartment complex in Nanjing, China, where all the residents worked at the hospital a block down the road. My grandmother would pick me up from school and bring me to her dermatology office. Around the same time, I also became interested in building and programming personal computers when home computers and the internet were becoming more popular. These experiences came together when I moved to the U.S. to attend the University of Texas at Austin. I studied the brain's contributions to our consciousness, learning behavior, the brain-immune interaction in the brain tumor setting and the mind-body connection with stress and sleep. These brain networks drew me to movement disorders. During my master's studies at Georgetown University and a year-long research project in Oregon afterward, I learned about integrative medicine, applying different health modalities to enhance quality of life — these intersect well with neurology's emphasis on interdisciplinary care and healing, especially in neurodegenerative diseases. I can empower my patients and their families and friends to live with their conditions, maximizing their quality of life and their health potential.

### Staying Informed and Curious

Combining research with care helps me to stay informed, stay curious and ensures I provide expert-level care. As a Fellow, I've learned more about neurophysiology, which assesses how your nervous system is functioning, especially its electrical activity, and correlative disease states and symptoms in Parkinson's, essential tremor and dystonia. I'm also designing and initiating several pilot clinical trials to apply neurophysiology-based artificial intelligence algorithms to predict the optimal DBS programming in these conditions. Clinically, I've been seeing patients, doing DBS programming and performing intraoperative microelectrode recording and testing in the operating room to help me transition into my practice next year. Our center also started offering MRI-guided focused ultrasound, and I collaborated with the neurosurgeons to participate in the care of the first three patients who underwent that treatment so far. For my next phase, I'll stay at the University of Florida Health as an assistant professor, focusing on DBS for movement disorders. The Fellowship has prepared me to be a successful movement disorders neurologist, and I've better defined my niche of clinical practice.

“Being a Fellow not only enabled me to deepen my clinical and research skills at a highly recognized institution under the supervision of highly qualified movement disorder specialists. It has also given me a new network of colleagues with whom I can share ideas and build new projects.”

— **Laura Armengou-García, MD**

Class of 2024

# *Fellowship Directors*

Class of 2024





Fellowship Directors  
Marcelo Merello, MD, PhD,  
Fleni Hospital, left; and David  
Standaert, MD, PhD, University  
of Alabama at Birmingham

## Christopher Caughman, MD

Emory University  
Atlanta, Georgia

Christopher Caughman is an assistant director in the Department of Neurology at Emory University and the fellowship director of the Movement Disorders Program at Emory Healthcare in Atlanta, Georgia. He is a graduate of Emory's Neurology Residency Program and was a recipient of the Edmond J. Safra Fellowship in Movement Disorders with the Class of 2021. As a clinician educator, Dr. Caughman works closely with medical students, residents and fellows at Emory. His clinical focus includes Parkinson's disease, essential tremor, dystonia and other movement disorders.

## Andres Deik, MD, MSEd, FAAN

University of Pennsylvania  
Philadelphia, Pennsylvania

Andres Deik is an associate professor of clinical neurology at the University of Pennsylvania and a movement disorders specialist in the Parkinson's Disease and Movement Disorders Center at Penn Medicine in Philadelphia. He focuses on clinical care, spearheads clinical trials and directs the Movement Disorders Fellowship. Awarded for teaching excellence at Penn's Perelman School of Medicine, Dr. Deik has overseen more than 20 Parkinson's clinical trials, gene therapy trials and studies on other neurological disorders such as dystonia and Huntington's disease. He is currently completing an investigator-initiated dystonia therapeutics trial.

## Hubert Fernandez, MD

Cleveland Clinic  
Cleveland, Ohio

Hubert Fernandez is professor of medicine at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and director of the Center for Neurological Restoration at the Cleveland Clinic in Cleveland, Ohio, where he also directs the Movement Disorders Fellowship. Dr. Fernandez has published more than 300 articles and abstracts on Parkinson's disease, cervical dystonia, blepharospasm and other movement disorders. He has also published 50 book chapters and a dozen books. Dr. Fernandez is the editor-in-chief of *Parkinsonism & Related Disorders* and an editorial board member of the *American Journal of Clinical Neurology*, *European Neurological Journal* and *Clinical Neuropharmacology*.

# Class of 2024

---

## Fellowship Directors

### Susan Fox, MB ChB, MRCP, PhD

University Health Network  
Toronto, Canada

Susan Fox is head of the Division of Neurology at the University Health Network (UHN) in Toronto, Canada, the Krembil Family Chair of Neurology at the University of Toronto and co-chair of UHN's Clinical Research Collaborative Centre. Dr. Fox is the past chair of the Pan-American section of the International Parkinson and Movement Disorder Society. With over 25 years of experience in preclinical models of Parkinson's disease and translational studies of novel pharmacological therapies for movement disorders, she has published more than 200 peer-reviewed papers, reviews and book chapters in the field and speaks regularly at national and international conferences.

### Christopher W. Hess, MD

University of Florida Health  
Gainesville, Florida

Christopher Hess is an assistant professor of neurology who serves as the director of neurotechnology and medical director and fellowship director at the Norman Fixel Institute for Neurological Diseases at University of Florida Health in Gainesville, Florida. He also directs the Parkinson's Disease Research, Education and Clinical Centers Consortium Center at the Gainesville VA Medical Center. Dr. Hess's research interests include wearable technologies in movement disorders and near-infrared light therapy for Parkinson's disease. He was recently the coordinating principal investigator on a multi-center study investigating the use of wearable devices for PD.

### Katie Kompoliti, MD

Rush University Medical Center  
Chicago, Illinois

Dr. Kompoliti is professor of neurology, educational director for the section of movement disorders in the Department of Neurological Sciences and director of the Movement Disorders Fellowship Program at Rush University Medical Center in Chicago, Illinois. She also directs Rush's Tourette Association Center of Excellence for Tourette syndrome and other tic disorders. An author and co-author of numerous publications, Dr. Kompoliti's clinical interests as a principal investigator have included studies to evaluate the safety and efficacy of new compounds to treat Parkinson's disease, other parkinsonian syndromes, Tourette syndrome and functional movement disorders.



Fellowship Directors Kailash Bhatia, MD, UCL Queen Square Institute of Neurology, left; and Susan Fox, MBChB, MRCP, PhD, Toronto Western Hospital

## Alexander Pantelyat, MD

Johns Hopkins University  
School of Medicine  
Baltimore, Maryland

Alexander Pantelyat is an associate professor of neurology, movement disorders neurologist, director of the Atypical Parkinsonism Center, co-founder and co-director of the Johns Hopkins Center for Music & Medicine and co-director of the Movement Disorders Fellowship at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Pantelyat's research explores atypical parkinsonian disorders such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders and music-based rehabilitation of neurodegenerative diseases.

## Bart Post, MD, Msc, PhD

Radboud University  
Medical Center  
Nijmegen, Netherlands

Bart Post is a movement disorder neurologist, co-director of the Parkinson Foundation Center of Excellence and chair of the residency program in the Department of Neurology at Radboud University Medical Center, Nijmegen, Netherlands. He has served on the steering committees of several large Parkinson trials, including LEAP (Levodopa in Early Parkinson's Disease), CHEVAL and FAIR-PARK. Within movement disorders, he is a member of the Multiple System Atrophy Study Group's rating scale committee, and a steering committee member of the Early-Onset Parkinson's Disease Study Group through the International Parkinson and Movement Disorder Society. Dr. Post has founded and organized several masterclasses on parkinsonisms and movement disorders in the Netherlands.

# The Edmond J. Safra Movement Disorders Research Career Development Awards

## 2023 Awardees



### Francesca Magrinelli, MD, PhD

Class of 2023

University College London  
London, England

Dr. Francesca Magrinelli recently discovered the *PSMF1* gene to be related to Parkinson's disease. With the Research Career Development Award, she seeks to explore how defects in *PSMF1* cause a spectrum from early-onset PD to perinatal lethality with neurological manifestations, and ultimately lead to neuronal loss. She will use a combination of genetics, transcriptomics, proteomics experiments and develop cell and animal models with defects in this gene to study how *PSMF1* impacts cell functioning. Dr. Magrinelli is six months into the two-year project and has already obtained solid preliminary results and promising findings to further develop.



### Kimberly Kwei, MD, PhD

Class of 2020

Columbia University  
New York, NY

Dr. Kimberly Kwei is seeking to understand the underlying biological pathways that lead to gait changes, particularly freezing of gait, in people with Parkinson's disease. She aims to do this by integrating assessments of gait — using video and wearable sensors — along with measurements of brain activity via deep brain stimulation electrodes and PET imaging. The project kicked off recently and the study team is initiating participant identification and recruitment. Dr. Kwei plans to seek additional funding from federal agencies using preliminary data generated from this study to further learnings gleaned from this project.

Launched in 2022 with support from the Edmond J. Safra Foundation, this competitive research funding opportunity from 2022 to 2024 aims to support the early career development and research trajectory of Edmond J. Safra Fellowship alumni. Awardees for the two-year pilot program were chosen based on the strength of the investigator, clarity of path to scientific independence and potential impact of the proposal. Each received a \$50K grant to support a two-year project.

## 2022 Inaugural Awardees



### Conor Fearon, BE, MB, PhD

Class of 2022

Dublin Neurological Institute  
Dublin, Ireland

Dr. Conor Fearon seeks to develop quantitative, clinically relevant biomarkers of Parkinson's disease to help differentiate between PD and related disorders through analysis of eye movements and pupillary response. Dr. Fearon has recruited a substantial number of participants and evaluated eye movements, while participants freely watch video clips in a natural way. Preliminary data from participants with Parkinson's demonstrate that saccades are smaller, slower and fewer in number than age-matched healthy controls and saccade velocity correlates with standard clinical measures. Additional more detailed analysis is ongoing.



### Anne Weissbach, MD

Class of 2020

The Institute of Neurogenetics in Lübeck  
Lübeck, Germany

Dr. Anne Weissbach seeks to examine people with mutations of different genes. She compares sensorimotor integration and clinical symptoms to investigate whether abnormalities in sensorimotor integration depend on the presence of symptoms of mutation carriers or if they are related to the genetic mutation. Dr. Weissbach and her team have established a mobile examination unit, enabling travel to participants in their home environments, for example, in the Philippines, to increase recruitment numbers. This year, Dr. Weissbach joined the permanent faculty of the University Clinic Schleswig-Holstein and applied for a full professorship to the University of Lübeck.

# *Fellows in Training*

---

The Edmond J. Safra Fellowship is currently supporting 16 movement disorder specialists in training at top-tier medical centers around the world.

## Class of 2025

### **William Barbosa, MD**

University of Rochester  
Rochester, New York

### **Juan Ramon Deliz, MD**

Northwestern University  
Chicago, Illinois

### **Kacey Hu, MD**

University of Southern California  
Keck School of Medicine  
Los Angeles, California

### **Taha Omer, MBBS, Dip.Ther, DCSM, MRCPI, MRCP (London), PhD**

University of Calgary  
Calgary, Canada

### **Emily Tharp, MD**

University of Texas Health Science Center  
Houston, Texas

### **Mehmet Salih Tuncer, MD**

Charité — Universitätsmedizin  
Berlin, Germany

### **Duncan Wilson, PhD, MRCP, MB ChB**

Westmead Hospital and University of Sydney  
Sydney, Australia

### **Isabel Wurster, MD**

University of Tübingen  
Tübingen, Germany

---

# Class of 2026

## **Sara Berman, MD, PhD**

University of Pennsylvania  
Philadelphia, Pennsylvania

## **Nicholas Bodnar, MD, PhD**

Brigham and Women's Hospital,  
Harvard Medical School  
Boston, Massachusetts

## **Patrick Cullinane, MB BCh, BAO, MSc, MRCPI**

University College London  
London, England

## **Carlos Lázaro Hernández, MD**

Fundació de Recerca Clínic Barcelona-Institut  
d'Investigacions Biomèdiques August Pi i Sunyer  
Barcelona, Spain

## **Sanne Meles, MD, PhD**

University Medical Center Groningen  
Groningen, Netherlands

## **Shashika Rodrigo, MD**

Rush University Medical Center  
Chicago, Illinois

## **Eshita Shah, MD, MS**

University of California San Diego  
San Diego, California

## **Viviana Torres Ballesteros, MD, MS**

University of Miami  
Coral Gables, Florida

# *Class of 2027*

## *Fellowship Centers*

The program recently selected eight international centers, two of which are new to the fellowship network, to train the tenth fellowship class.

Each center will now identify a candidate to begin two years of training in July 2025.

### **Dublin Neurological Institute at the Mater and St. Vincent's University Hospital**

Dublin, Ireland

### **Cleveland Clinic**

Cleveland, Ohio

### **Fleni Hospital**

Buenos Aires, Argentina

### **Hospital de Clínicas de Porto Alegre**

Porto Alegre, Brazil

### **Mount Sinai Hospital**

New York, New York

### **University of California, San Francisco**

San Francisco, California

### **University of Florida College of Medicine**

Gainesville, Florida

### **University of Sydney and Westmead Hospital**

Sydney, Australia





# The Edmond J. Safra Fellowship

## A Decade of Training Leaders

### Graduated Fellows

#### Class of 2018

**David P. Breen, BSc(Hons), MBChB, PhD, FRCP**  
Toronto Western Hospital

**Marissa Dean, MD**  
University of Alabama at Birmingham

**Lenora Higginbotham, MD**  
Emory University

**Christine Kim, MD,**  
Columbia University

**Gerrit Machetanz, MD**  
University of Tübingen

#### Class of 2019

**Katherine Amodeo, MD**  
University of Rochester

**Sarah Horn, MD**  
University of Pennsylvania

**Katherine Leaver, MD**  
Mount Sinai Hospital

**Jessica Weinstein, MD**  
University of California, San Francisco

**Natalie Witek, MD, MS**  
Rush University Medical Center

#### Class of 2020

**Juliana Coleman, MD**  
University of Alabama at Birmingham

**Grace Crotty, MD, MB BCH BAO, MRCPI, MPH**  
Massachusetts General Hospital

**Eric Jackowiak, MD**  
University of Michigan

**Greg Kuhlman, MD, MBA**  
Toronto Western Hospital

**Kimberly Kwei, MD, PhD**  
Columbia University

**Anne Weissbach, MD**  
University of Lübeck

#### Class of 2021

**Whitley Aamodt, MD, MPH, MSCE**  
University of Pennsylvania

**Amir A. Badiei, MD, MS**  
University of California, San Francisco

**Christopher Caughman, MD**  
Emory University

**Judith van Gaalen, MD**  
Radboud University Medical Centre

**Neil Shetty, MD,**  
Northwestern University

#### Class of 2022

**Aditya Boddu, MD**  
University of Alabama at Birmingham

**Conor Fearon, BE, MB, PhD**  
Toronto Western Hospital

**Eoin Mulroy, MB BCH, BAO, FRACP**  
UCL Queen Square Institute of Neurology

**Chintan Shah, MD**  
Baylor College of Medicine

**Jon Toledo Atucha, MD, PhD**  
University of Florida-Shands Health Center

**Pavan Vaswani, MD, PhD**  
University of Pennsylvania

#### Class of 2023

**Sergio Andrés Castillo-Torres, MD**  
Fleni Hospital

**Stephen Joza, MD, PhD**  
McGill University/Montreal Neurological Institute

**Francesca Magrinelli, MD, PhD**  
UCL Queen Square Institute of Neurology

**Poornima Jayadev Menon, MB BCH BAO, LRCP & SI, MRCPI, DTMH**  
Pitié-Salpêtrière Hospital

**Andrea Sujung Yoo, MD**  
Mount Sinai Hospital

#### Class of 2024

**Laura Armengou-García, MD**  
Toronto Western Hospital

**Milan Beckers, MSc**  
Radboud University Medical Centre

**Stephen Berger, MD, PhD**  
Johns Hopkins University School of Medicine

**José Ricardo López Castellanos, MD**  
Emory University

**Leila Saadatpour, MD**  
Cleveland Clinic

**Christina Swan, MD, PhD**  
Rush University Medical Center

**Rebecca Williamson, MD, PhD**  
University of Pennsylvania

**Jun Yu, MD, MS**  
University of Florida-Shands Health Center

## Fellowship Centers and Directors

### **Baylor College of Medicine**

Joseph Jankovic, MD

### **Brigham and Women's Hospital, Harvard Medical School**

Barbara Changizi, MD

### **Charité – Universitätsmedizin**

Andrea Kühn, MD;  
Christos Ganos, MD

### **Cleveland Clinic**

Hubert Fernandez, MD

### **Columbia University**

Un Jung Kang, MD;  
Oren Levy, MD, PhD;  
Blair Ford, MD

### **Dublin Neurological Institute at the Mater and St. Vincent's University Hospital**

Timothy Lynch, MB, BSc,  
DCH, FRCPI, FRCP, Dmed

### **Emory University**

Stewart Factor, DO

### **Fleni Hospital**

Marcelo Merello, MD, PhD

### **Fundació de Recerca Clínic Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)**

Francesc Valldeoriola,  
MD, PhD

### **Hospital de Clínicas de Porto Alegre**

Artur Schumacher-Schuh,  
MD, PhD

### **Johns Hopkins University School of Medicine**

Alexander Pantelyat, MD

### **Massachusetts General Hospital**

Alice Flaherty, MD, PhD

### **McGill University/Montreal Neurological Institute**

Ronald Postuma, MD, MSc

### **Mount Sinai Hospital**

Susan Bressman, MD;  
Rachel Saunders-Pullman,  
MD, MPH, MS

### **Northwestern University**

Tanya Simuni, MD

### **Pitié-Salpêtrière Hospital**

Jean-Christophe Corvol,  
MD, PhD

### **Radboud University Medical Centre**

Bart van de Warrenburg, MD,  
PhD; Bart Post, MD, Msc,  
PhD; Bastiaan (Bas) Bloem,  
MD, PhD

### **Rush University**

Katie Kompolti, MD

### **Toronto Western Hospital**

Susan Fox, MBChB, MRCP,  
PhD; Anthony Lang, MD,  
FRCPC

### **UCL Queen Square Institute of Neurology**

Kailash Bhatia, MD;  
Sonia Gandhi, BMBCh, PhD

### **University Medical Center Groningen**

Marina de Koning-Tijssen,  
MD, PhD; Teus van Laar, MD,  
PhD

### **University of Alabama at Birmingham**

David Standaert, MD, PhD

### **University of Calgary**

Justyna Sarna, MD, PhD

### **University of California, San Diego**

David Coughlin, MD;  
Caitlin Mulligan, MD

### **University of California, San Francisco**

Rafael Zuzuárregui, MD;  
Ethan Brown, MD

### **University of Florida-Shands Health Center**

Christopher W. Hess, MD

### **University of Lübeck**

Christine Klein, MD

### **University of Miami**

Corneliu Luca, MD, PhD;  
Danielle Shpiner, MD;  
Ihtsham Haq, MD

### **University of Michigan**

Praveen Dayalu, MD

### **University of Pennsylvania**

Andres Deik, MD, MSc;  
James F Morley, MD, PhD;  
Pavan Vaswani, MD, PhD;  
Nabila Dahodwala, MD, MS

### **University of Rochester**

Irene Richard, MD;  
Jamie Adams, MD

### **University of Southern California Keck School of Medicine**

Mark Lew, MD;  
Emily Tamadonfar, MD;  
Katherine (Kat) Wong, MD;  
Xenos Mason, MD

### **University of Texas Health Science Center**

Mya Schiess, MD

### **University of Tübingen**

Thomas Gasser, MD, PhD

### **Westmead Hospital and University of Sydney**

Victor Fung, MBBS, PhD;  
Neil Mahant, MBBS, PhD



**THE MICHAEL J. FOX FOUNDATION  
FOR PARKINSON'S RESEARCH**

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding \$2 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide

Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

[michaeljfox.org](http://michaeljfox.org)



**EDMOND J. SAFRA  
PHILANTHROPIC FOUNDATION**

Edmond J. Safra, one of the 20th century's most accomplished bankers and a devoted philanthropist, established a major charitable foundation to ensure that individuals and organizations would continue to receive his assistance and encouragement for many years to come. Led for more than 20 years by his beloved wife Lily, the Edmond J. Safra Foundation draws continuing inspiration from Mr. and Mrs. Safra's values and priorities, supporting

hundreds of organizations and programs in more than 40 countries around the world. Its work encompasses four areas: education; science and medicine; religion; and humanitarian assistance, culture and social welfare. The Foundation has provided significant funding for Parkinson's disease research and patient care at dozens of hospitals and institutes in places as varied as Natal (Brazil), Toronto, New York, Grenoble, Paris, London and Jerusalem.

[edmondjsafra.org](http://edmondjsafra.org)

---

## Credits

Fellow biographies as told to Sarah Jackson

Illustrations by Nancy Januzzi

# The Michael J. Fox Foundation

## Founder

Michael J. Fox

## Chief Executive Officer and Co-founder

Deborah W. Brooks

## Chief Mission Officer

Todd Sherer, PhD

## Chief Development Officer

Lisa Boudreau

## Chief Marketing Officer

Holly Teichholtz

## Principal Medical Advisor

Rachel Dolhun, MD,  
DipABLM

## Board and Councils

### Board of Directors

Skip Irving, Chairman  
Jeff Keefer, Vice Chairman  
Holly S. Andersen, MD  
Bonnie M. Bandeen  
Glenn Batchelder  
Susan Bilotta  
Mark Booth  
Jon Brooks  
Barry J. Cohen  
Andrew Creighton  
John S. Daly  
Frank D'Amelio  
Donny Deutsch  
David Einhorn  
Karen Finerman  
Nelle Fortenberry  
Akbar Gbajabiamila  
Willie Geist  
Gabe Gelman  
David Glickman  
Anne M. Holloway  
Melanie Bolch Isbill  
Edward Kalikow  
Alex Krysz  
Amar Kuchinad  
Marc S. Lipschultz  
Barry Malkin  
Colin R. Masson  
Ofer Nemirovsky  
Andrew J. O'Brien  
Douglas I. Ostrover  
Lisa A. Piazza, MD  
Tracy Pollan  
Jack F. Quinn  
Ryan Reynolds  
Hartley T. Richardson  
Ari Richter  
Frederick E. Rowe  
Carolyn Schenker  
Curtis Schenker  
Richard J. Schnall  
Woody Shackleton  
Anne-Cecilie Engell Speyer  
George Stephanopoulos  
Bonnie Strauss  
Rick Tigner  
Fred G. Weiss  
Sonny Whelen  
Peter Zaffino

### Founders' Council

Lonnie and Muhammad Ali  
Steven A. Cohen  
Albert B. Glickman  
David Golub  
John Griffin  
Andrew S. Grove  
Katie Hood  
Jeffrey Katzenberg  
Morton M. Kondracke  
Edwin A. Levy  
Nora McAniff  
Lily Safra  
Donna Shalala, PhD

### Leadership Council

Richard Fitzgerald, Chairman  
Omar Abdel-Hafez  
Shakeeb Alam  
Loren Berger  
Felix Bhandari  
Zachary Brez  
Alexandra Cherubini  
Dev Chodry  
Taryn Fixel  
Michael Howard  
Michael Kaplan  
Julia Kelly  
Matthew Levy  
Pamela Mirels  
Vikas Mohindra  
Daniel Morris  
Daisy Prince  
Rafi Rosman  
Scott Scheffrin  
Bill Shepherd  
Ryan Squillante  
Meredith Tutterow

### Patient Council

Lynn Hagerbrant, Co-chair  
Bret Parker, Co-chair  
Matt Ackerman  
Eugenia Brin  
Bill Bucklew  
Ken Cater  
Leonard Chandler  
Jimmy Choi  
Denise Coley  
Fiona Davis

María L. De León, MD  
Peter DiBiaso  
Anne Cohn Donnelly, DPH  
Hadley Ferguson  
Michael S. Fitts  
Bill Geist  
Larry Gifford  
Ethan Henderson  
Kathy Holden  
Richard Huckabee  
Karen Jaffe, MD  
Sebastian Krysz  
Wanda Kim Lilley  
Sheryl Lowenhar  
Soania Mathur, MD  
Jim McNasby  
Rebecca Miller, PhD  
Hilton Mirels, MD  
David Nutter  
Matthew Peck  
Gary Rafaloff  
Bill Rasmussen  
Claudia Revilla  
Bryan M. Roberts  
Israel Robledo  
John Seibyl  
Margaret Sheehan  
Allie Signorelli  
M. Daniel Suwyn

### Patient Council

#### **Emeritus Members**


Carl Bolch, Jr.  
Christopher Chadbourne  
Carey Christensen  
Quentin Dastugue  
Steven D. DeWitte  
David Eger, PhD  
Cynthia Gray  
David Iverson  
Nicole Jarvis, MD  
Richie Rothenberg

### Patient Council

#### **Legacy Members**

Michael R. "Rich" Clifford  
Tony Mendez  
Tom Picone  
Eric Pitcher  
W.N. "Bill" Wilkins

 michaeljfoxfoundation

 @michaeljfoxorg

 michaeljfox

michaeljfox.org

1 800-708-7644